Bristol's Eliquis approved to prevent clots after hip, knee surgery

March 14 Fri Mar 14, 2014 1:17pm EDT

March 14 (Reuters) - U.S. regulators have approved an additional use of Bristol-Myers Squibb Co's blood clot preventer Eliquis, to prevent blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees.

The drug is already sold in partnership with Pfizer Inc to prevent blood clots that can cause strokes in patients with atrial fibrillation, an irregular heartbeat that is most common in the elderly.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.